OSE Immunotherapeutics Announces Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, for CD28 Antagonist VEL-101/FR104
Based on the global license agreement signed in April 2021, this first milestone triggers a…
AI Turns Vulnerability Management Into a Throughput Problem
Neutrik® Connects Made-To-Order, High-Performance AV Solutions For RCI Custom
AceDraft Announces AceDraft, a Free ATS Resume Tool to Help Gen Z Job Seekers Match Job Descriptions
uSMART Becomes the World’s First Technology Brokerage to Offer Both ‘Night and Pre-Market Trading’ in U.S. Options
Chervon Names Doug Palmer Vice President of Finance – Canada